Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arcus Biosciences, Inc. (RCUS)
USD27.93
-0.40 (-1.41%)
US NYSE Healthcare Biotechnology
Address
3928 Point Eden Way 94545
Hayward, CA, US
Hayward, CA, US
CEO
Terry J. Rosen
Website
arcusbio.com
IPO
2018-03-14
CIK 1724521 ISIN US03969F1093
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD27.93
-0.40 (-1.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.84
Float Shares
75.95M
Free Float %
75.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.97% | -3.27% | +11.28% | +24.55% | +24.30% | +4.32% | +182.50% | +34.52% | -14.72% | +46.24% | +46.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
27.93
Low
22.00
-21.2%
Consensus
30.33
+8.6%
Median
29.00
+3.8%
High
47.00
+68.3%
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 9 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
47.00
+68.3%
|
| Last Quarter | 2 |
35.00
+25.3%
|
| Last Year | 11 |
29.45
+5.4%
|
| All Time | 22 |
31.91
+14.2%
|
Quality scores
Altman Z-Score
0.82
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-4.3% Q1'26: -39.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-4.8% Q1'26: +10.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-218.2% Q1'26: -811.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-139.7% Q1'26: -788.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +270.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+19.2% Q1'26: +27.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.30× Q1'26: -0.19× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 5 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 9 Rev. Ana. 7 EPS Ana. |
Dec 2029 4 Rev. Ana. 2 EPS Ana. |
Dec 2030 4 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.35M
est: 7.75M (+7.8%)
|
15.00M
est: 6.46M (+132.2%)
|
78.00M
est: 75.97M (+2.7%)
|
383.00M
est: 40.33M (+849.7%)
|
112.00M
est: 102.64M (+9.1%)
|
117.00M
est: 247.00M (-52.6%)
|
258.00M
est: 261.59M (-1.4%)
|
247.00M
est: 246.54M (+0.2%)
|
89.62M
50.92M – 225.85M
-63.6% YoY
|
92.65M
19.57M – 176.12M
+3.4% YoY
|
185.02M
179.71M – 190.32M
+99.7% YoY
|
442.76M
199.60M – 889.02M
+139.3% YoY
|
939.23M
423.42M – 1.89B
+112.1% YoY
|
| EBITDA |
-51.20M
est: -5.96M (-759.1%)
|
-81.13M
est: -4.97M (-1,532.8%)
|
-120.00M
est: -88.84M (-35.1%)
|
59.00M
est: -31.02M (+290.2%)
|
-258.00M
est: -78.95M (-226.8%)
|
-291.00M
est: -189.99M (-53.2%)
|
-269.00M
est: -201.21M (-33.7%)
|
-335.00M
est: -189.63M (-76.7%)
|
-68.94M
-173.72M – -39.17M
+63.6% YoY
|
-71.27M
-135.47M – -15.05M
-3.4% YoY
|
-142.31M
-146.39M – -138.23M
-99.7% YoY
|
-340.57M
-683.82M – -153.53M
-139.3% YoY
|
-722.44M
-1.45B – -325.69M
-112.1% YoY
|
| EBIT |
-54.86M
est: -5.98M (-818.1%)
|
-84.71M
est: -4.98M (-1,600.2%)
|
-123.00M
est: -93.78M (-31.2%)
|
55.00M
est: -31.10M (+276.8%)
|
-264.00M
est: -79.17M (-233.5%)
|
-299.00M
est: -190.51M (-57.0%)
|
-279.00M
est: -201.76M (-38.3%)
|
-345.00M
est: -190.15M (-81.4%)
|
-69.12M
-174.20M – -39.27M
+63.6% YoY
|
-71.46M
-135.84M – -15.09M
-3.4% YoY
|
-142.70M
-146.79M – -138.61M
-99.7% YoY
|
-341.49M
-685.68M – -153.95M
-139.3% YoY
|
-724.41M
-1.45B – -326.57M
-112.1% YoY
|
| Net Income |
-49.59M
est: -166.05M (+70.1%)
|
-84.71M
est: -180.52M (+53.1%)
|
-123.00M
est: -92.57M (-32.9%)
|
53.00M
est: 1.59B (-96.7%)
|
-267.00M
est: -287.00M (+7.0%)
|
-307.00M
est: -249.00M (-23.3%)
|
-283.00M
est: -298.00M (+5.0%)
|
-353.00M
est: -369.00M (+4.3%)
|
-467.09M
-565.57M – -260.77M
-26.6% YoY
|
-431.41M
-469.54M – -225.62M
+7.6% YoY
|
-211.13M
-311.34M – -110.91M
+51.1% YoY
|
-63.37M
-146.39M – -18.13M
+70.0% YoY
|
204.24M
58.42M – 471.85M
+422.3% YoY
|
| SGA |
13.57M
est: 4.85M (+179.5%)
|
25.23M
est: 4.05M (+523.3%)
|
43.00M
est: 37.79M (+13.8%)
|
72.00M
est: 25.27M (+184.9%)
|
104.00M
est: 64.31M (+61.7%)
|
117.00M
est: 149.53M (-21.8%)
|
120.00M
est: 158.37M (-24.2%)
|
110.00M
est: 149.25M (-26.3%)
|
54.26M
30.83M – 136.73M
-63.6% YoY
|
56.09M
11.85M – 106.62M
+3.4% YoY
|
112.01M
108.80M – 115.22M
+99.7% YoY
|
268.05M
120.84M – 538.21M
+139.3% YoY
|
568.61M
256.34M – 1.14B
+112.1% YoY
|
| EPS |
-1.43
est: -1.84 (+22.4%)
|
-1.73
est: -2.00 (+13.7%)
|
-2.13
est: -2.18 (+2.2%)
|
0.76
est: -4.35 (+117.5%)
|
-3.71
est: -3.88 (+4.4%)
|
-4.15
est: -3.05 (-36.3%)
|
-3.14
est: -3.41 (+7.9%)
|
-3.29
est: -3.55 (+7.4%)
|
-3.83
-5.27 – -2.43
-7.8% YoY
|
-3.36
-4.37 – -2.10
+12.3% YoY
|
-2.09
-2.90 – -1.03
+38.0% YoY
|
-0.59
-1.36 – -0.17
+71.7% YoY
|
1.90
0.54 – 4.39
+422.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-454.19M
OE per share TTM
-4.05
Owner's Yield
-13.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
36.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
29
Total invested
11.28M
Insider transactions (90d)
0
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 29.50M | 35.00% | 29.50M | — | 29.50M | 11.00 | CO | — | 2020-07-17 | ↗ |
| 2 | (1) BlackRock, Inc. | 9.73M | 10.60% | 9.54M | — | 9.73M | — | HC | Delaware | 2024-11-08 | ↗ |
| 3 | (1)Names of reporting persons. BlackRock, Inc. | 7.97M | 11.10% | 7.86M | — | 7.97M | — | HC | Delaware | 2022-05-09 | ↗ |
| 4 | Abigail P. Johnson | 4.73M | 6.32% | — | — | 4.73M | — | IN | United States of America | 2024-02-09 | ↗ |
| 5 | FMR LLC | 4.73M | 6.32% | 4.73M | — | 4.73M | — | HC | Delaware | 2024-02-09 | ↗ |
| 6 | EcoR1 Capital, LLC | 4.57M | 11.00% | — | — | 4.57M | 4.57M | IA, OO | Delaware | 2021-07-19 | ↗ |
| 7 | Oleg Nodelman | 4.57M | 11.00% | — | — | 4.57M | 4.57M | HC, IN | Delaware | 2021-07-19 | ↗ |
| 8 | The Vanguard Group - 23-1945930 | 4.37M | 6.04% | — | 34.5K | — | — | IA | Pennsylvania | 2023-02-09 | ↗ |
| 9 | Terry Rosen, Ph.D. | 4.29M | 9.34% | 269.6K | 4.02M | 269.6K | 10.00 | IN | Delaware | 2020-03-05 | ↗ |
| 10 | Wellington Group Holdings LLP | 4.28M | 9.64% | — | 4.09M | — | — | HC | Delaware | 2019-02-12 | ↗ |
| 11 | Wellington Investment Advisors Holdings LLP | 4.28M | 9.64% | — | 4.09M | — | — | HC | Delaware | 2019-02-12 | ↗ |
| 12 | Wellington Management Group LLP | 4.28M | 9.64% | — | 4.09M | — | — | HC | Massachusetts | 2019-02-12 | ↗ |
| 13 | STATE STREET CORPORATION | 4.24M | 5.66% | — | 4.11M | — | 4.24M | HC | BOSTON, MASSACHUSETTS | 2024-01-24 | ↗ |
| 14 | Wellington Management Company LLP | 4.08M | 9.18% | — | 4.04M | — | — | IA | Delaware | 2019-02-12 | ↗ |
| 15 | Victoria Rosen | 4.02M | 8.77% | — | 4.02M | — | 10.00 | IN | Delaware | 2020-03-05 | ↗ |
| 16 | EcoR1 Capital Fund Qualified, L.P. | 3.99M | 11.00% | — | 3.99M | — | 3.99M | PN | Delaware | 2021-07-19 | ↗ |
| 17 | BVF Inc. | 3.96M | 5.60% | — | — | — | 3.96M | CO | Delaware | 2022-03-14 | ↗ |
| 18 | BVF Partners L.P. | 3.96M | 5.60% | — | — | — | 3.96M | IA, PN | Delaware | 2022-03-14 | ↗ |
| 19 | Mark N. Lampert | 3.96M | 5.60% | — | — | — | 3.96M | IN | Delaware | 2022-03-14 | ↗ |
| 20 | BVF GP Holdings LLC | 3.70M | 5.20% | — | — | — | 3.70M | OO | Delaware | 2022-03-14 | ↗ |
| 21 | The Rosen 1996 Family Trust | 3.02M | 6.59% | 3.02M | — | 3.02M | 10.00 | OO | Delaware | 2020-03-05 | ↗ |
| 22 | Boxer Asset Management Inc. | 3.02M | 6.60% | — | 3.02M | — | 3.02M | CO | — | 2020-02-13 | ↗ |
| 23 | Joe Lewis | 3.02M | 6.60% | — | 3.02M | — | 3.02M | IN | — | 2020-02-13 | ↗ |
| 24 | BVF I GP LLC | 2.16M | 3.00% | — | — | — | 2.16M | OO | Delaware | 2022-03-14 | ↗ |
| 25 | Biotechnology Value Fund, L.P. | 2.16M | 3.00% | — | — | — | 2.16M | PN | Delaware | 2022-03-14 | ↗ |
| 26 | Boxer Capital, LLC | 2.08M | 3.20% | — | 2.08M | — | 2.08M | OO | Delaware | 2021-02-16 | ↗ |
| 27 | 13G | 1.92M | 4.33% | 1.92M | — | 1.92M | — | PN | Delaware | 2019-02-12 | ↗ |
| 28 | Juan Jaen, Ph.D. | 1.89M | 2.92% | 322.7K | 1.57M | 322.7K | 10.00 | IN | Delaware | 2020-10-15 | ↗ |
| 29 | Anita Galeana | 1.57M | 2.42% | — | 1.57M | — | 10.00 | IN | Delaware | 2020-10-15 | ↗ |
| 30 | Juan Carlos Jaen and Anita Galeana 2000 Trust | 1.57M | 2.42% | 1.57M | — | 1.57M | 10.00 | OO | Delaware | 2020-10-15 | ↗ |
| 31 | BVF II GP LLC | 1.54M | 2.20% | — | — | — | 1.54M | OO | Delaware | 2022-03-14 | ↗ |
| 32 | Biotechnology Value Fund II, L.P. | 1.54M | 2.20% | — | — | — | 1.54M | PN | Delaware | 2022-03-14 | ↗ |
| 33 | GV 2016, L.P. | 639.0K | 0.91% | 1.92M | 1.92M | 1.92M | 1.92M | PN | Delaware | 2022-02-14 | ↗ |
| 34 | BVF Partners OS Ltd. | 194.5K | 1.00% | — | — | — | 194.5K | CO | Delaware | 2022-03-14 | ↗ |
| 35 | Biotechnology Value Trading Fund OS LP | 194.5K | 1.00% | — | — | — | 194.5K | PN | Delaware | 2022-03-14 | ↗ |
| 36 | 2. | 10.00 | 5.50% | — | 3.93M | — | — | IA, PN | Delaware | 2022-10-17 | ↗ |
| 37 | PFM Health Sciences, LP | 6.00 | 5.20% | — | 3.37M | — | 3.37M | IA, PN, IN | Delaware | 2020-11-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
29
-194 vs prev Q
New positions
5
Closed positions
184
Increased
10
Reduced
9
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 916.3K +916.3K (+100.0%) | 21.84B +21.8B (+100.0%) | 0.86% +0.860 pp | 5.40% +5.395 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 379.1K +379.1K (+100.0%) | 9.03B +9.0B (+100.0%) | 0.36% +0.356 pp | 0.01% +0.014 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 3 | GILEAD SCIENCES, INC. | 31.42M +— (+0.0%) | 748.85M +321.5M (+75.2%) | 29.51% -0.111 pp | 38.69% +14.834 pp | USD14.58 +63.4% | 5 qtrs — |
| 4 | BLACKROCK, INC. | 15.00M +3.2M (+27.0%) | 357.40M +196.8M (+122.5%) | 14.08% +2.951 pp | 0.01% +0.003 pp | USD16.20 +47.1% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 7.96M +1.3M (+20.1%) | 189.76M +99.6M (+110.5%) | 7.48% +1.229 pp | 0.00% +0.001 pp | USD20.34 +17.2% | 32 qtrs — |
| 6 | SUVRETTA CAPITAL MANAGEMENT, LLC | 5.19M +1.5M (+40.7%) | 123.65M +73.5M (+146.5%) | 4.87% +1.395 pp | 2.53% +1.249 pp | USD13.70 +73.9% | 10 qtrs — |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 5.18M +3.9M (+309.4%) | 123.55M +106.3M (+617.4%) | 4.87% +3.675 pp | 0.02% +0.019 pp | USD20.29 +17.4% | 4 qtrs — |
| 8 | STATE STREET CORP | 4.58M +1.2M (+34.8%) | 109.07M +62.9M (+136.2%) | 4.30% +1.098 pp | 0.00% +0.002 pp | USD20.21 +17.9% | 31 qtrs — |
| 9 | WOODLINE PARTNERS LP | 3.77M +104.0 (+0.0%) | 89.83M +38.6M (+75.2%) | 3.54% -0.013 pp | 0.35% +0.107 pp | USD14.44 +65.0% | 13 qtrs — |
| 10 | MARSHALL WACE, LLP | 3.39M +3.4M (+100.0%) | 80.73M +80.7M (+100.0%) | 3.18% +3.181 pp | 0.07% +0.074 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 11 | POINT72 ASSET MANAGEMENT, L.P. | 3.28M -1.1M (-24.3%) | 78.16M +19.2M (+32.7%) | 3.08% -1.004 pp | 0.09% -0.011 pp | USD11.36 +109.8% | 14 qtrs — |
| 12 | SIREN, L.L.C. | 3.01M +95.0K (+3.3%) | 71.66M +32.1M (+80.9%) | 2.82% +0.079 pp | 2.14% +0.588 pp | USD14.83 +60.7% | 6 qtrs — |
| 13 | FISHER ASSET MANAGEMENT, LLC | 1.95M +1.2M (+167.4%) | 46.46M +36.5M (+368.5%) | 1.83% +1.144 pp | 0.02% +0.012 pp | USD19.74 +20.7% | 4 qtrs — |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.91M +308.9K (+19.3%) | 45.46M +23.7M (+109.1%) | 1.79% +0.284 pp | 0.00% +0.001 pp | USD17.23 +38.3% | 31 qtrs — |
| 15 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 1.69M +267.4K (+18.8%) | 40.21M +20.9M (+108.2%) | 1.58% +0.246 pp | 0.05% -0.004 pp | USD20.18 +18.1% | 19 qtrs — |
| 16 | SAMLYN CAPITAL, LLC | 1.60M +1.6M (+100.0%) | 38.23M +38.2M (+100.0%) | 1.51% +1.506 pp | 0.61% +0.609 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 17 | DIMENSIONAL FUND ADVISORS LP | 1.52M +21.7K (+1.4%) | 36.32M +15.9M (+77.7%) | 1.43% +0.015 pp | 0.01% +0.003 pp | USD21.98 +8.4% | 26 qtrs — |
| 18 | TORONTO DOMINION BANK | 1.48M +1.5M (+100.0%) | 35.38M +35.4M (+100.0%) | 1.39% +1.394 pp | 0.05% +0.052 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 19 | MORGAN STANLEY | 1.21M -325.3K (-21.2%) | 28.85M +8.0M (+38.1%) | 1.14% -0.311 pp | 0.00% +0.001 pp | USD12.89 +84.9% | 32 qtrs — |
| 20 | GOLDMAN SACHS GROUP INC | 1.17M +217.8K (+22.9%) | 27.84M +14.9M (+115.4%) | 1.10% +0.201 pp | 0.00% +0.002 pp | USD15.39 +54.8% | 32 qtrs — |
| 21 | FMR LLC | 1.14M -1.2M (-50.6%) | 27.05M -4.2M (-13.4%) | 1.07% -1.098 pp | 0.00% 0.000 pp | USD22.08 +7.9% | 24 qtrs — |
| 22 | BARCLAYS PLC | 1.11M +993.6K (+837.1%) | 26.51M +24.7M (+1,360.5%) | 1.04% +0.933 pp | 0.01% +0.006 pp | USD22.67 +5.1% | 31 qtrs — |
| 23 | SOFINNOVA INVESTMENTS, INC. | 1.10M -125.6K (-10.3%) | 26.13M +9.5M (+57.2%) | 1.03% -0.122 pp | 1.13% +0.218 pp | USD7.92 +200.9% | 4 qtrs — |
| 24 | LOGOS GLOBAL MANAGEMENT LP | 1.05M +1.1M (+100.0%) | 25.02M +25.0M (+100.0%) | 0.99% +0.986 pp | 1.51% +1.512 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 25 | BANK OF AMERICA CORP /DE/ | 1.00M -360.0K (-26.5%) | 23.85M +5.3M (+28.9%) | 0.94% -0.343 pp | 0.00% +0.001 pp | USD12.85 +85.4% | 32 qtrs — |
| 26 | PARKMAN HEALTHCARE PARTNERS LLC | 968.6K +315.9K (+48.4%) | 23.08M +14.2M (+160.0%) | 0.91% +0.294 pp | 2.20% +1.271 pp | USD18.67 +27.6% | 23 qtrs — |
| 27 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 968.2K +97.1K (+11.1%) | 23.07M +11.2M (+94.7%) | 0.91% +0.088 pp | 0.00% +0.002 pp | USD16.20 +47.1% | 31 qtrs — |
| 28 | JACOBS LEVY EQUITY MANAGEMENT, INC | 930.0K -190.1K (-17.0%) | 22.16M +6.9M (+45.5%) | 0.87% -0.182 pp | 0.09% +0.025 pp | USD11.89 +100.4% | 10 qtrs — |
| 29 | FRANKLIN RESOURCES INC | 853.5K +853.5K (+100.0%) | 20.34M +20.3M (+100.0%) | 0.80% +0.801 pp | 0.01% +0.005 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 30 | BALYASNY ASSET MANAGEMENT L.P. | 815.6K +715.2K (+712.5%) | 19.43M +18.1M (+1,323.7%) | 0.77% +0.671 pp | 0.02% +0.023 pp | USD21.90 +8.8% | 6 qtrs — |
| 31 | NORTHERN TRUST CORP | 794.8K +87.0K (+12.3%) | 18.94M +9.3M (+96.8%) | 0.75% +0.079 pp | 0.00% +0.001 pp | USD16.76 +42.2% | 31 qtrs — |
| 32 | CANDRIAM S.C.A. | 790.6K +412.2K (+108.9%) | 18.84M +13.7M (+266.1%) | 0.74% +0.386 pp | 0.09% +0.067 pp | USD18.93 +25.9% | 2 qtrs — |
| 33 | CAPTION MANAGEMENT, LLC | 767.7K +767.7K (+100.0%) | 18.29M +18.3M (+100.0%) | 0.72% +0.721 pp | 0.13% +0.126 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 34 | SOLEUS CAPITAL MANAGEMENT, L.P. | 712.0K +712.0K (+100.0%) | 16.97M +17.0M (+100.0%) | 0.67% +0.669 pp | 0.63% +0.626 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 35 | FIRST TURN MANAGEMENT, LLC | 565.1K +565.1K (+100.0%) | 13.47M +13.5M (+100.0%) | 0.53% +0.531 pp | 1.54% +1.539 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 36 | DECHENG CAPITAL LLC | 541.6K -6.1K (-1.1%) | 12.91M +5.5M (+73.3%) | 0.51% -0.008 pp | 1.74% +0.437 pp | USD15.21 +56.7% | 9 qtrs — |
| 37 | BANK OF NEW YORK MELLON CORP | 504.5K +34.3K (+7.3%) | 12.02M +5.6M (+88.0%) | 0.47% +0.031 pp | 0.00% +0.001 pp | USD19.53 +22.0% | 31 qtrs — |
| 38 | DAFNA CAPITAL MANAGEMENT LLC | 431.3K -196.3K (-31.3%) | 10.28M +1.7M (+20.4%) | 0.41% -0.187 pp | 2.39% +0.279 pp | USD13.84 +72.2% | 24 qtrs — |
| 39 | BNP PARIBAS ARBITRAGE, SNC | 424.1K +340.0K (+404.7%) | 10.11M +9.0M (+784.4%) | 0.40% +0.319 pp | 0.00% +0.004 pp | USD21.86 +9.0% | 31 qtrs — |
| 40 | INVESCO LTD. | 414.4K +122.0K (+41.7%) | 9.87M +5.9M (+148.3%) | 0.39% +0.114 pp | 0.00% +0.001 pp | USD19.06 +25.0% | 24 qtrs — |
| 41 | UBS GROUP AG | 411.3K +243.9K (+145.7%) | 9.80M +7.5M (+330.5%) | 0.39% +0.228 pp | 0.00% +0.001 pp | USD20.53 +16.1% | 31 qtrs — |
| 42 | PRINCIPAL FINANCIAL GROUP INC | 407.5K +73.0K (+21.8%) | 9.71M +5.2M (+113.5%) | 0.38% +0.067 pp | 0.01% +0.003 pp | USD21.70 +9.8% | 21 qtrs — |
| 43 | PDT PARTNERS, LLC | 388.3K +— (+0.0%) | 9.25M +4.0M (+75.2%) | 0.36% -0.001 pp | 0.60% +0.267 pp | USD10.21 +133.4% | 9 qtrs — |
| 44 | ABRDN PLC | 384.6K +52.9K (+16.0%) | 9.17M +4.7M (+107.5%) | 0.36% +0.049 pp | 0.01% +0.007 pp | USD15.01 +58.8% | 2 qtrs — |
| 45 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 341.9K -47.3K (-12.1%) | 8.15M +2.9M (+53.9%) | 0.32% -0.046 pp | 0.00% +0.000 pp | USD10.84 +119.8% | 23 qtrs — |
| 46 | AFFINITY ASSET ADVISORS, LLC | 300.0K +300.0K (+100.0%) | 7.15M +7.1M (+100.0%) | 0.28% +0.282 pp | 0.41% +0.407 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 47 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 295.4K +25.6K (+9.5%) | 7.04M +3.4M (+91.8%) | 0.28% +0.023 pp | 0.02% +0.010 pp | USD16.08 +48.2% | 15 qtrs — |
| 48 | BAKER BROS. ADVISORS LP | 270.0K +270.0K (+100.0%) | 6.43M +6.4M (+100.0%) | 0.25% +0.254 pp | 0.04% +0.038 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 49 | HUDSON BAY CAPITAL MANAGEMENT LP | 240.0K -100.0K (-29.4%) | 5.72M +1.1M (+23.7%) | 0.23% -0.095 pp | 0.02% +0.004 pp | USD12.49 +90.8% | 16 qtrs — |
| 50 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 240.0K +— (+0.0%) | 5.72M +2.5M (+75.2%) | 0.23% -0.001 pp | 0.09% +0.037 pp | USD8.14 +192.8% | 3 qtrs — |
| 51 | RHUMBLINE ADVISERS | 227.1K +17.5K (+8.4%) | 5.41M +2.6M (+89.9%) | 0.21% +0.016 pp | 0.00% +0.002 pp | USD18.80 +26.8% | 29 qtrs — |
| 52 | AMERIPRISE FINANCIAL INC | 225.9K +16.1K (+7.7%) | 5.38M +2.5M (+88.6%) | 0.21% +0.014 pp | 0.00% +0.001 pp | USD18.05 +32.0% | 15 qtrs — |
| 53 | TUDOR INVESTMENT CORP ET AL | 208.6K +208.6K (+100.0%) | 4.97M +5.0M (+100.0%) | 0.20% +0.196 pp | 0.01% +0.009 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 54 | LEGAL & GENERAL GROUP PLC | 205.2K +26.8K (+15.0%) | 4.89M +2.5M (+101.5%) | 0.19% +0.025 pp | 0.00% +0.001 pp | USD22.42 +6.3% | 31 qtrs — |
| 55 | NICHOLAS INVESTMENT PARTNERS, LP | 204.3K +204.3K (+100.0%) | 4.87M +4.9M (+100.0%) | 0.19% +0.192 pp | 0.35% +0.355 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 56 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 203.3K +117.2K (+136.2%) | 4.84M +3.7M (+313.9%) | 0.19% +0.110 pp | 0.01% +0.009 pp | USD19.50 +22.2% | 2 qtrs — |
| 57 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 180.0K +180.0K (+100.0%) | 4.29M +4.3M (+100.0%) | 0.17% +0.169 pp | 0.22% +0.220 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 58 | PATIENT SQUARE CAPITAL LP | 170.0K +170.0K (+100.0%) | 4.05M +4.1M (+100.0%) | 0.16% +0.160 pp | 0.87% +0.867 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 59 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 169.9K -285.7K (-62.7%) | 4.05M -2.1M (-34.6%) | 0.16% -0.270 pp | 0.17% -0.080 pp | USD17.79 +34.0% | 18 qtrs — |
| 60 | MILLENNIUM MANAGEMENT LLC | 168.9K -466.1K (-73.4%) | 4.02M -4.6M (-53.4%) | 0.16% -0.440 pp | 0.00% -0.002 pp | USD13.38 +78.1% | 27 qtrs — |
| 61 | SWISS NATIONAL BANK | 168.0K +34.5K (+25.8%) | 4.00M +2.2M (+120.5%) | 0.16% +0.032 pp | 0.00% +0.001 pp | USD17.81 +33.8% | 29 qtrs — |
| 62 | UBS ASSET MANAGEMENT AMERICAS INC | 144.1K +56.3K (+64.2%) | 3.43M +2.2M (+187.7%) | 0.14% +0.053 pp | 0.00% +0.001 pp | USD19.60 +21.6% | 23 qtrs — |
| 63 | ALYESKA INVESTMENT GROUP, L.P. | 142.5K +142.5K (+100.0%) | 3.40M +3.4M (+100.0%) | 0.13% +0.134 pp | 0.01% +0.010 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 64 | NUVEEN, LLC | 141.6K +14.8K (+11.6%) | 3.37M +1.6M (+95.6%) | 0.13% +0.013 pp | 0.00% +0.000 pp | USD9.52 +150.3% | 4 qtrs — |
| 65 | TWO SIGMA INVESTMENTS, LP | 139.6K -331.9K (-70.4%) | 3.33M -3.1M (-48.1%) | 0.13% -0.313 pp | 0.00% -0.005 pp | USD11.72 +103.3% | 10 qtrs — |
| 66 | RUSSELL INVESTMENTS GROUP, LTD. | 136.1K +53.9K (+65.5%) | 3.24M +2.1M (+190.1%) | 0.13% +0.050 pp | 0.00% +0.002 pp | USD16.41 +45.2% | 13 qtrs — |
| 67 | PLATINUM INVESTMENT MANAGEMENT LTD | 134.2K -19.6K (-12.7%) | 3.20M +1.1M (+52.9%) | 0.13% -0.019 pp | 0.74% +0.604 pp | USD17.72 +34.5% | 32 qtrs — |
| 68 | ALLIANCEBERNSTEIN L.P. | 133.1K -4.1K (-3.0%) | 3.17M +1.3M (+70.0%) | 0.13% -0.004 pp | 0.00% +0.000 pp | USD17.83 +33.7% | 29 qtrs — |
| 69 | AMERICAN CENTURY COMPANIES INC | 128.9K +3.4K (+2.7%) | 3.07M +1.4M (+79.9%) | 0.12% +0.003 pp | 0.00% +0.001 pp | USD18.83 +26.6% | 21 qtrs — |
| 70 | KNOTT DAVID M JR | 121.2K +26.0K (+27.4%) | 2.89M +1.6M (+123.2%) | 0.11% +0.024 pp | 1.34% +0.816 pp | USD12.62 +88.8% | 4 qtrs — |
| 71 | LMR PARTNERS LLP | 100.0K +100.0K (+100.0%) | 2.38M +2.4M (+100.0%) | 0.09% +0.094 pp | 0.00% +0.005 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 72 | WELLS FARGO & COMPANY/MN | 99.3K +31.0K (+45.4%) | 2.37M +1.4M (+154.7%) | 0.09% +0.029 pp | 0.00% +0.000 pp | USD17.36 +37.3% | 32 qtrs — |
| 73 | SCHONFELD STRATEGIC ADVISORS LLC | 97.3K +48.4K (+99.0%) | 2.32M +1.7M (+248.6%) | 0.09% +0.045 pp | 0.01% +0.007 pp | USD19.91 +19.7% | 21 qtrs — |
| 74 | CITADEL ADVISORS LLC | 94.6K -8.9K (-8.6%) | 2.25M +846.7K (+60.2%) | 0.09% -0.009 pp | 0.00% +0.000 pp | USD11.91 +100.1% | 22 qtrs — |
| 75 | RAFFERTY ASSET MANAGEMENT, LLC | 92.9K +23.3K (+33.4%) | 2.21M +1.3M (+133.8%) | 0.09% +0.022 pp | 0.01% +0.005 pp | USD19.37 +23.0% | 23 qtrs — |
| 76 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 92.4K +1.0K (+1.1%) | 2.20M +960.0K (+77.2%) | 0.09% +0.001 pp | 0.00% +0.002 pp | USD24.07 -1.0% | 15 qtrs — |
| 77 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 90.7K +26.7K (+41.7%) | 2.16M +1.3M (+148.2%) | 0.09% +0.025 pp | 0.00% +0.001 pp | USD17.07 +39.6% | 31 qtrs — |
| 78 | PARALLEL ADVISORS, LLC | 86.6K -1.5K (-1.6%) | 2.06M +865.8K (+72.3%) | 0.08% -0.002 pp | 0.04% +0.016 pp | USD9.24 +157.9% | 27 qtrs — |
| 79 | AQR CAPITAL MANAGEMENT LLC | 86.2K +2.4K (+2.9%) | 2.05M +914.9K (+80.3%) | 0.08% +0.002 pp | 0.00% +0.000 pp | USD10.53 +126.3% | 9 qtrs — |
| 80 | D. E. SHAW & CO., INC. | 85.6K +65.7K (+330.6%) | 2.04M +1.8M (+654.5%) | 0.08% +0.062 pp | 0.00% +0.001 pp | USD20.12 +18.4% | 8 qtrs — |
| 81 | THRIVENT FINANCIAL FOR LUTHERANS | 80.4K +30.5K (+61.1%) | 1.92M +1.2M (+182.2%) | 0.08% +0.028 pp | 0.00% +0.002 pp | USD23.06 +3.3% | 15 qtrs — |
| 82 | PRUDENTIAL FINANCIAL INC | 79.5K +9.2K (+13.1%) | 1.89M +937.9K (+98.1%) | 0.07% +0.008 pp | 0.00% +0.001 pp | USD20.29 +17.4% | 25 qtrs — |
| 83 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 73.9K +14.6K (+24.7%) | 1.76M +970.0K (+122.9%) | 0.07% +0.014 pp | 0.00% +0.002 pp | USD21.87 +9.0% | 29 qtrs — |
| 84 | JPMORGAN CHASE & CO | 72.8K +8.8K (+13.8%) | 1.73M +864.1K (+99.4%) | 0.07% +0.008 pp | 0.00% +0.000 pp | USD18.10 +31.7% | 32 qtrs — |
| 85 | DEUTSCHE BANK AG\ | 62.7K +14.3K (+29.6%) | 1.49M +835.6K (+127.1%) | 0.06% +0.013 pp | 0.00% +0.000 pp | USD20.50 +16.2% | 31 qtrs — |
| 86 | WINTON GROUP LTD | 62.3K -30.0K (-32.5%) | 1.48M +229.1K (+18.3%) | 0.06% -0.029 pp | 0.05% +0.004 pp | USD13.60 +75.2% | 8 qtrs — |
| 87 | DARK FOREST CAPITAL MANAGEMENT LP | 60.6K -79.4K (-56.7%) | 1.44M -459.9K (-24.1%) | 0.06% -0.075 pp | 0.07% +0.009 pp | USD8.83 +169.9% | 10 qtrs — |
| 88 | STATE OF WISCONSIN INVESTMENT BOARD | 58.8K +28.1K (+91.5%) | 1.40M +984.3K (+235.6%) | 0.06% +0.026 pp | 0.00% +0.002 pp | USD20.44 +16.6% | 28 qtrs — |
| 89 | PRICE T ROWE ASSOCIATES INC /MD/ | 58.6K +9.3K (+18.9%) | 1.40M +726.0K (+108.0%) | 0.06% +0.009 pp | 0.00% +0.000 pp | USD17.46 +36.5% | 22 qtrs — |
| 90 | SECTORAL ASSET MANAGEMENT INC | 56.9K -311.1K (-84.5%) | 1.36M -3.6M (-72.9%) | 0.05% -0.293 pp | 1.09% -2.002 pp | USD10.66 +123.5% | 24 qtrs — |
| 91 | FORT BAKER CAPITAL MANAGEMENT LP | 52.5K +52.5K (+100.0%) | 1.25M +1.3M (+100.0%) | 0.05% +0.049 pp | 0.14% +0.137 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 92 | NOMURA HOLDINGS INC | 51.1K +30.0K (+142.2%) | 1.22M +930.8K (+324.3%) | 0.05% +0.028 pp | 0.00% +0.001 pp | USD17.35 +37.3% | 3 qtrs — |
| 93 | BURKEHILL GLOBAL MANAGEMENT, LP | 50.0K +50.0K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.05% +0.047 pp | 0.08% +0.079 pp | USD23.83 +0.0% | 1 qtrs NEW |
| 94 | JANE STREET GROUP, LLC | 46.5K -179.1K (-79.4%) | 1.11M -2.0M (-63.9%) | 0.04% -0.169 pp | 0.00% 0.000 pp | USD10.02 +137.8% | 23 qtrs — |
| 95 | SG AMERICAS SECURITIES, LLC | 45.5K +12.7K (+38.8%) | 1.08M +638.0K (+143.0%) | 0.04% +0.012 pp | 0.00% 0.000 pp | USD14.85 +60.5% | 9 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 137 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF IDNA | 2.66% | 5.22M | 0.47% |
| 2 | Tema Oncology ETF CANC | 1.25% | 1.78M | 0.75% |
| 3 | Invesco S&P SmallCap Health Care ETF PSCH | 1.10% | 1.79M | 0.29% |
| 4 | Virtus Biotech Clinical Trials ETF BBC | 0.75% | 430.5K | 0.65% |
| 5 | Global X - S&P Biotech ETF CURE.AX | 0.69% | 249.1K | 0.45% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.69% | 75.04M | 0.35% |
| 7 | iShares Health Innovation Active ETF BMED | 0.67% | 74.2K | 0.77% |
| 8 | First Trust Nasdaq Pharmaceuticals ETF FTXH | 0.66% | 241.0K | 0.60% |
| 9 | Invesco S&P SmallCap Momentum ETF XSMO | 0.49% | 15.11M | 0.36% |
| 10 | Invesco Dorsey Wright SmallCap Momentum ETF DWAS | 0.44% | 2.08M | 0.60% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
4
Shares acquired
—
Shares disposed
66.8K
Cash buys
—
Cash sales
3.00
Net activity
-66,823
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-23 | Tang Carolyn C. | Officer | A-Award | A | Stock Option (right to buy) | 96,000 | 22.13 | 2.12M | 96,000 | D | ↗ |
| 2026-01-23 | ROSEN TERRY J | Director / Officer | A-Award | A | Stock Option (right to buy) | 315,000 | 22.13 | 6.97M | 315,000 | D | ↗ |
| 2026-01-23 | Markus Richard | Officer | A-Award | A | Stock Option (right to buy) | 96,000 | 22.13 | 2.12M | 96,000 | D | ↗ |
| 2026-01-23 | Jarrett Jennifer | Officer | A-Award | A | Stock Option (right to buy) | 126,000 | 22.13 | 2.79M | 126,000 | D | ↗ |
| 2026-01-23 | Jaen Juan C. | Officer | A-Award | A | Common Stock | 31,000 | 0.00 | — | 377,012 | D | ↗ |
| 2026-01-23 | Goeltz II Robert C. | Officer | A-Award | A | Common Stock | 24,000 | 0.00 | — | 91,924 | D | ↗ |
| 2026-01-23 | Azoy Alexander | Officer | A-Award | A | Common Stock | 21,050 | 0.00 | — | 39,581 | D | ↗ |
| 2026-01-08 | ROSEN TERRY J | Director / Officer | G-Gift | D | Common Stock | 35,000 | 0.00 | — | 2,157,409 | D | ↗ |
| 2026-01-05 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 2,053 | 22.34 | 45.9K | 922,340 | I | ↗ |
| 2025-12-31 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 6,552 | 23.38 | 153.2K | 67,924 | D | ↗ |
| 2025-12-30 | ROSEN TERRY J | Director / Officer | G-Gift | D | Common Stock | 2,400 | 0.00 | — | 2,192,409 | D | ↗ |
| 2025-12-18 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 4,343 | 22.25 | 96.6K | 18,531 | D | ↗ |
| 2025-12-17 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 6,810 | 22.16 | 150.9K | 124,734 | D | ↗ |
| 2025-12-17 | ROSEN TERRY J | Director / Officer | S-Sale | D | Common Stock | 25,744 | 22.16 | 570.5K | 2,194,809 | D | ↗ |
| 2025-12-17 | Markus Richard | Officer | S-Sale | D | Common Stock | 4,494 | 22.16 | 99.6K | 65,647 | D | ↗ |
| 2025-12-17 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 9,983 | 22.16 | 221.2K | 193,024 | D | ↗ |
| 2025-12-17 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 9,983 | 22.16 | 221.2K | 346,012 | D | ↗ |
| 2025-12-17 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 5,960 | 22.16 | 132.1K | 74,476 | D | ↗ |
| 2025-12-17 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 2,113 | 22.16 | 46.8K | 22,874 | D | ↗ |
| 2025-12-16 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 7,658 | 21.88 | 167.6K | 131,544 | D | ↗ |
| 2025-12-16 | ROSEN TERRY J | Director / Officer | S-Sale | D | Common Stock | 28,947 | 21.88 | 633.5K | 2,220,553 | D | ↗ |
| 2025-12-16 | Markus Richard | Officer | S-Sale | D | Common Stock | 5,052 | 21.88 | 110.6K | 70,141 | D | ↗ |
| 2025-12-16 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 11,225 | 21.88 | 245.7K | 203,007 | D | ↗ |
| 2025-12-16 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 11,225 | 21.88 | 245.7K | 355,995 | D | ↗ |
| 2025-12-16 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 6,702 | 21.88 | 146.7K | 80,436 | D | ↗ |
| 2025-12-16 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 2,376 | 21.88 | 52.0K | 24,987 | D | ↗ |
| 2025-12-04 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 82,997 | 24.71 | 2.05M | 954,063 | I | ↗ |
| 2025-11-26 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 5,000 | 25.00 | 125.0K | 87,138 | D | ↗ |
| 2025-11-26 | Azoy Alexander | Officer | M-Exempt | A | Common Stock | 1,900 | 13.33 | 25.3K | 29,263 | D | ↗ |
| 2025-11-18 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 5,050 | 19.75 | 99.7K | 1,037,060 | I | ↗ |
| 2025-11-17 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 37,114 | 20.23 | 750.7K | 1,049,946 | I | ↗ |
| 2025-11-07 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 50,291 | 18.97 | 954.1K | 214,232 | D | ↗ |
| 2025-10-30 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 4,314 | 20.32 | 87.6K | 1,087,060 | I | ↗ |
| 2025-10-29 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 47,675 | 20.49 | 976.8K | 1,121,539 | I | ↗ |
| 2025-10-28 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 19,019 | 20.19 | 383.9K | 1,169,214 | I | ↗ |
| 2025-10-28 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 5,000 | 20.00 | 100.0K | 92,138 | D | ↗ |
| 2025-10-08 | Jarrett Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 37,792 | 1.23 | 46.4K | 130,874 | D | ↗ |
| 2025-10-06 | Jarrett Jennifer | Officer | M-Exempt | A | Common Stock | 12,500 | 1.23 | 15.3K | 226,732 | D | ↗ |
| 2025-09-29 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 2,831 | 13.00 | 36.8K | 27,363 | D | ↗ |
| 2025-09-05 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 1,579 | 11.88 | 18.8K | 30,194 | D | ↗ |
| 2025-06-10 | Ribas Antoni | Director | A-Award | A | Stock Option (Right to Buy) | 38,300 | 10.02 | 383.8K | 38,300 | D | ↗ |
| 2025-06-10 | PERLMAN ANDREW J | Director | A-Award | A | Stock Option (Right to Buy) | 38,300 | 10.02 | 383.8K | 38,300 | D | ↗ |
| 2025-06-10 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 38,300 | 10.02 | 383.8K | 38,300 | D | ↗ |
| 2025-06-10 | Lambert Nicole | Director | A-Award | A | Common Stock | 13,300 | 0.00 | — | 37,300 | D | ↗ |
| 2025-06-10 | Lacey David L. | Director | A-Award | A | Stock Option (Right to Buy) | 38,300 | 10.02 | 383.8K | 38,300 | D | ↗ |
| 2025-06-10 | KANEKO YASUNORI | Director | A-Award | A | Common Stock | 13,300 | 0.00 | — | 33,300 | D | ↗ |
| 2025-06-10 | FALBERG KATHRYN E | Director | A-Award | A | Stock Option (Rights to Buy) | 38,300 | 10.02 | 383.8K | 38,300 | D | ↗ |
| 2025-02-27 | ROSEN TERRY J | Director / Officer | P-Purchase | A | Common Stock | 19,800 | 10.18 | 201.5K | 2,554,160 | D | ↗ |
| 2025-02-27 | KANEKO YASUNORI | Director | P-Purchase | A | Common Stock | 20,000 | 10.06 | 201.2K | 28,400 | D | ↗ |
| 2025-02-18 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Common Stock | 1,363,636 | 11.00 | 15.00M | 31,424,760 | D | ↗ |
| 2025-02-10 | Markus Richard | Officer | A-Award | A | Common Stock | 75,193 | 0.00 | — | 75,193 | D | ↗ |
| 2025-02-06 | Berger Dietmar | Director | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-01-31 | Markus Richard | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-01-23 | Tang Carolyn C. | Officer | A-Award | A | Common Stock | 37,000 | 0.00 | — | 137,623 | D | ↗ |
| 2025-01-23 | Ribas Antoni | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 13.33 | 66.7K | 5,000 | D | ↗ |
| 2025-01-23 | ROSEN TERRY J | Director / Officer | A-Award | A | Common Stock | 165,000 | 0.00 | — | 2,534,360 | D | ↗ |
| 2025-01-23 | Lacey David L. | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 13.33 | 66.7K | 5,000 | D | ↗ |
| 2025-01-23 | Jarrett Jennifer | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 13.33 | 2.67M | 200,000 | D | ↗ |
| 2025-01-23 | Jaen Juan C. | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 13.33 | 2.67M | 200,000 | D | ↗ |
| 2025-01-23 | Goeltz II Robert C. | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 13.33 | 2.00M | 150,000 | D | ↗ |
| 2025-01-23 | Azoy Alexander | Officer | A-Award | A | Stock Option (right to buy) | 11,400 | 13.33 | 152.0K | 11,400 | D | ↗ |
| 2024-12-31 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 3,594 | 15.00 | 53.9K | 60,138 | D | ↗ |
| 2024-12-19 | Azoy Alexander | Officer | D-Return | D | Common Stock | 3,007 | 15.17 | 45.6K | 13,094 | D | ↗ |
| 2024-12-15 | Tang Carolyn C. | Officer | F-InKind | D | Common Stock | 11,339 | 16.08 | 182.3K | 100,623 | D | ↗ |
| 2024-12-15 | ROSEN TERRY J | Director / Officer | F-InKind | D | Common Stock | 37,882 | 16.08 | 609.1K | 2,369,360 | D | ↗ |
| 2024-12-15 | Nuyten Dimitry SA | Officer | F-InKind | D | Common Stock | 7,856 | 16.08 | 126.3K | 87,518 | D | ↗ |
| 2024-12-15 | Jarrett Jennifer | Officer | F-InKind | D | Common Stock | 27,501 | 16.08 | 442.2K | 163,369 | D | ↗ |
| 2024-12-15 | Jaen Juan C. | Officer | F-InKind | D | Common Stock | 17,286 | 16.08 | 278.0K | 317,220 | D | ↗ |
| 2024-12-15 | Goeltz II Robert C. | Officer | F-InKind | D | Common Stock | 10,099 | 16.08 | 162.4K | 63,732 | D | ↗ |
| 2024-12-15 | Azoy Alexander | Officer | F-InKind | D | Common Stock | 2,969 | 16.08 | 47.7K | 16,101 | D | ↗ |
| 2024-12-02 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 201 | 15.32 | 3.1K | 19,070 | D | ↗ |
| 2024-09-15 | Nuyten Dimitry SA | Officer | F-InKind | D | Common Stock | 5,385 | 17.95 | 96.7K | 94,933 | — | ↗ |
| 2024-09-15 | Jarrett Jennifer | Officer | F-InKind | D | Common Stock | 12,670 | 17.95 | 227.4K | 190,394 | — | ↗ |
| 2024-08-13 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 1,357 | 14.97 | 20.3K | 19,070 | — | ↗ |
| 2024-06-15 | Tang Carolyn C. | Officer | F-InKind | D | Common Stock | 4,182 | 16.97 | 71.0K | 111,364 | — | ↗ |
| 2024-06-15 | ROSEN TERRY J | Director / Officer | F-InKind | D | Common Stock | 12,670 | 16.97 | 215.0K | 3,954,304 | — | ↗ |
| 2024-06-15 | Jarrett Jennifer | Officer | F-InKind | D | Common Stock | 12,670 | 16.97 | 215.0K | 203,064 | — | ↗ |
| 2024-06-15 | Jaen Juan C. | Officer | F-InKind | D | Common Stock | 6,969 | 16.97 | 118.3K | 334,506 | — | ↗ |
| 2024-06-06 | Ribas Antoni | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 15.90 | 381.6K | 24,000 | — | ↗ |
| 2024-06-06 | PERLMAN ANDREW J | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 15.90 | 381.6K | 24,000 | — | ↗ |
| 2024-06-06 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 15.90 | 381.6K | 24,000 | — | ↗ |
| 2024-06-06 | Lambert Nicole | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 15.90 | 381.6K | 24,000 | — | ↗ |
| 2024-06-06 | Lacey David L. | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 15.90 | 381.6K | 24,000 | — | ↗ |
| 2024-06-06 | KANEKO YASUNORI | Director | A-Award | A | Common Stock | 8,400 | 0.00 | — | 15,200 | — | ↗ |
| 2024-06-06 | FALBERG KATHRYN E | Director | A-Award | A | Common Stock | 8,400 | 0.00 | — | 55,300 | — | ↗ |
| 2024-03-27 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 11,551 | 17.55 | 202.7K | 215,253 | — | ↗ |
| 2024-03-18 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 12,153 | 17.84 | 216.8K | 228,100 | — | ↗ |
| 2024-02-27 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 34,070 | 20.11 | 685.1K | 240,253 | — | ↗ |
| 2024-02-27 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 23,132 | 20.10 | 465.0K | 1,188,233 | — | ↗ |
| 2024-02-26 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 24,555 | 20.07 | 492.8K | 274,323 | — | ↗ |
| 2024-02-26 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 3,900 | 20.06 | 78.2K | 1,211,365 | — | ↗ |
| 2024-01-29 | Mercier Johanna | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-29 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Common Stock | 15,238,095 | 21.00 | 320.00M | 30,061,124 | — | ↗ |
| 2024-01-23 | Tang Carolyn C. | Officer | A-Award | A | Common Stock | 26,700 | 0.00 | — | 114,579 | — | ↗ |
| 2024-01-23 | ROSEN TERRY J | Director / Officer | A-Award | A | Stock Option (right to buy) | 405,900 | 15.44 | 6.27M | 405,900 | — | ↗ |
| 2024-01-23 | Nuyten Dimitry SA | Officer | A-Award | A | Common Stock | 28,000 | 0.00 | — | 99,195 | — | ↗ |
| 2024-01-23 | Jarrett Jennifer | Director / Officer | A-Award | A | Stock Option (right to buy) | 162,400 | 15.44 | 2.51M | 162,400 | — | ↗ |
| 2024-01-23 | Jaen Juan C. | Director / Officer | A-Award | A | Stock Option (right to buy) | 162,400 | 15.44 | 2.51M | 162,400 | — | ↗ |
| 2024-01-23 | Goeltz II Robert C. | Officer | A-Award | A | Common Stock | 22,000 | 0.00 | — | 73,831 | — | ↗ |
| 2024-01-23 | Azoy Alexander | Officer | A-Award | A | Stock Option (right to buy) | 5,900 | 15.44 | 91.1K | 5,900 | — | ↗ |
| 2024-01-02 | Jaen Juan C. | Director / Officer | S-Sale | D | Common Stock | 6,975 | 20.09 | 140.1K | 1,215,265 | — | ↗ |
| 2024-01-02 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 2,004 | 20.00 | 40.1K | 51,831 | — | ↗ |
| 2023-12-29 | ROSEN TERRY J | Director / Officer | W-Will | A | Common Stock | 448 | 0.00 | — | 3,866,974 | — | ↗ |
| 2023-12-22 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 21,521 | 17.76 | 382.2K | 258,878 | — | ↗ |
| 2023-12-20 | Azoy Alexander | Officer | D-Return | D | Common Stock | 68 | 18.21 | 1.2K | 10,220 | — | ↗ |
| 2023-12-19 | Tang Carolyn C. | Officer | D-Return | D | Common Stock | 4,076 | 18.09 | 73.7K | 87,879 | — | ↗ |
| 2023-12-19 | ROSEN TERRY J | Director / Officer | D-Return | D | Common Stock | 14,000 | 18.09 | 253.3K | 3,866,526 | — | ↗ |
| 2023-12-19 | Nuyten Dimitry SA | Officer | D-Return | D | Common Stock | 1,540 | 18.09 | 27.9K | 71,195 | — | ↗ |
| 2023-12-19 | Jarrett Jennifer | Director / Officer | D-Return | D | Common Stock | 11,492 | 18.09 | 207.9K | 280,399 | — | ↗ |
| 2023-12-19 | Jaen Juan C. | Director / Officer | D-Return | D | Common Stock | 6,259 | 18.09 | 113.2K | 301,475 | — | ↗ |
| 2023-12-19 | Goeltz II Robert C. | Officer | D-Return | D | Common Stock | 2,808 | 18.09 | 50.8K | 53,835 | — | ↗ |
| 2023-12-19 | Azoy Alexander | Officer | D-Return | D | Common Stock | 661 | 18.09 | 12.0K | 10,288 | — | ↗ |
| 2023-12-18 | Tang Carolyn C. | Officer | D-Return | D | Common Stock | 3,991 | 17.74 | 70.8K | 91,955 | — | ↗ |
| 2023-12-18 | ROSEN TERRY J | Director / Officer | D-Return | D | Common Stock | 13,705 | 17.74 | 243.1K | 3,880,526 | — | ↗ |
| 2023-12-18 | Nuyten Dimitry SA | Officer | D-Return | D | Common Stock | 1,507 | 17.74 | 26.7K | 72,735 | — | ↗ |
| 2023-12-18 | Jarrett Jennifer | Director / Officer | D-Return | D | Common Stock | 11,250 | 17.74 | 199.6K | 291,891 | — | ↗ |
| 2023-12-18 | Jaen Juan C. | Director / Officer | D-Return | D | Common Stock | 6,128 | 17.74 | 108.7K | 307,734 | — | ↗ |
| 2023-12-18 | Goeltz II Robert C. | Officer | D-Return | D | Common Stock | 2,749 | 17.74 | 48.8K | 56,643 | — | ↗ |
| 2023-12-18 | Azoy Alexander | Officer | D-Return | D | Common Stock | 647 | 17.74 | 11.5K | 10,949 | — | ↗ |
| 2023-12-01 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 282 | 14.95 | 4.2K | 11,596 | — | ↗ |
| 2023-09-22 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 21,369 | 19.99 | 427.2K | 302,691 | — | ↗ |
| 2023-09-18 | Nuyten Dimitry SA | Officer | D-Return | D | Common Stock | 3,708 | 20.40 | 75.6K | 73,591 | — | ↗ |
| 2023-09-18 | Jarrett Jennifer | Director / Officer | D-Return | D | Common Stock | 12,506 | 20.40 | 255.1K | 324,060 | — | ↗ |
| 2023-07-28 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 45,000 | 20.25 | 911.3K | 336,566 | — | ↗ |
| 2023-07-03 | Azoy Alexander | Officer | S-Sale | D | Common Stock | 1,018 | 20.41 | 20.8K | 11,596 | — | ↗ |
| 2023-06-28 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Common Stock | 1,010,000 | 19.26 | 19.45M | 14,823,029 | — | ↗ |
| 2023-06-22 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 12,437 | 19.12 | 237.8K | 381,566 | — | ↗ |
| 2023-06-16 | Tang Carolyn C. | Officer | D-Return | D | Common Stock | 2,892 | 19.35 | 56.0K | 95,902 | — | ↗ |
| 2023-06-16 | ROSEN TERRY J | Director / Officer | D-Return | D | Common Stock | 8,762 | 19.35 | 169.5K | 3,894,231 | — | ↗ |
| 2023-06-16 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 12,563 | 19.35 | 243.1K | 394,003 | — | ↗ |
| 2023-06-16 | Jaen Juan C. | Director / Officer | D-Return | D | Common Stock | 4,820 | 19.35 | 93.3K | 313,862 | — | ↗ |
| 2023-06-15 | Ribas Antoni | Director | A-Award | A | Common Stock | 6,800 | 0.00 | — | 21,950 | — | ↗ |
| 2023-06-15 | PERLMAN ANDREW J | Director | A-Award | A | Stock Option (Right to Buy) | 19,500 | 19.60 | 382.2K | 19,500 | — | ↗ |
| 2023-06-15 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 19,500 | 19.60 | 382.2K | 19,500 | — | ↗ |
| 2023-06-15 | Lambert Nicole | Director | A-Award | A | Common Stock | 6,800 | 0.00 | — | 15,600 | — | ↗ |
| 2023-06-15 | Lacey David L. | Director | A-Award | A | Stock Option (Right to Buy) | 19,500 | 19.60 | 382.2K | 19,500 | — | ↗ |
| 2023-06-15 | KANEKO YASUNORI | Director | A-Award | A | Stock Option (Right to Buy) | 19,500 | 19.60 | 382.2K | 19,500 | — | ↗ |
| 2023-06-15 | Jaen Juan C. | Director / Officer | G-Gift | D | Common Stock | 6,000 | 0.00 | — | 318,682 | — | ↗ |
| 2023-06-15 | FALBERG KATHRYN E | Director | A-Award | A | Stock Option (Right to Buy) | 19,500 | 19.60 | 382.2K | 19,500 | — | ↗ |
| 2023-06-07 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 4,049 | 20.04 | 81.1K | 59,392 | — | ↗ |
| 2023-03-16 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 8,729 | 16.81 | 146.7K | 406,217 | — | ↗ |
| 2023-03-09 | Azoy Alexander | Officer | — | D | Common Stock | 0 | 0.00 | — | 216 | — | ↗ |
| 2023-01-27 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 1,600 | 23.52 | 37.6K | 414,946 | — | ↗ |
| 2023-01-26 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 300 | 23.56 | 7.1K | 416,546 | — | ↗ |
| 2023-01-23 | Tang Carolyn C. | Officer | A-Award | A | Stock Option (right to buy) | 138,200 | 0.00 | — | 138,200 | — | ↗ |
| 2023-01-23 | ROSEN TERRY J | Officer | A-Award | A | Stock Option (right to buy) | 429,000 | 0.00 | — | 429,000 | — | ↗ |
| 2023-01-23 | Nuyten Dimitry SA | Officer | A-Award | A | Common Stock | 34,000 | 0.00 | — | 76,500 | — | ↗ |
| 2023-01-23 | Jarrett Jennifer | Officer | A-Award | A | Common Stock | 45,800 | 0.00 | — | 416,846 | — | ↗ |
| 2023-01-23 | Jaen Juan C. | Officer | A-Award | A | Stock Option (right to buy) | 185,900 | 0.00 | — | 185,900 | — | ↗ |
| 2023-01-23 | Goeltz II Robert C. | Officer | A-Award | A | Common Stock | 34,000 | 0.00 | — | 63,441 | — | ↗ |
| 2022-12-16 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 2,125 | 30.66 | 65.2K | 28,982 | — | ↗ |
| 2022-12-16 | ROSEN TERRY J | Officer | S-Sale | D | Common Stock | 10,983 | 30.66 | 336.7K | 244,233 | — | ↗ |
| 2022-12-16 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 2,603 | 31.23 | 81.3K | 147,609 | — | ↗ |
| 2022-12-16 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 701 | 31.23 | 21.9K | 218,258 | — | ↗ |
| 2022-12-16 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 387 | 31.23 | 12.1K | 11,566 | — | ↗ |
| 2022-08-23 | Nuyten Dimitry SA | Officer | A-Award | A | Stock Option (Right to Buy) | 170,000 | 26.00 | 4.42M | 170,000 | — | ↗ |
| 2022-08-01 | Nuyten Dimitry SA | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-17 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 449 | 21.71 | 9.7K | 24,982 | — | ↗ |
| 2022-06-17 | Jaen Juan C. | Director / Officer | S-Sale | D | Common Stock | 1,789 | 22.29 | 39.9K | 210,037 | — | ↗ |
| 2022-06-16 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 1,073 | 22.29 | 23.9K | 23,909 | — | ↗ |
| 2022-06-16 | ROSEN TERRY J | Officer | S-Sale | D | Common Stock | 1,361 | 21.71 | 29.5K | 230,968 | — | ↗ |
| 2022-06-16 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 4,663 | 22.29 | 103.9K | 118,619 | — | ↗ |
| 2022-06-16 | Jaen Juan C. | Officer | S-Sale | D | Common Stock | 2,333 | 20.72 | 48.3K | 212,574 | — | ↗ |
| 2022-06-14 | Ribas Antoni | Director | A-Award | A | Common Stock | 4,100 | 0.00 | — | 15,150 | — | ↗ |
| 2022-06-14 | PERLMAN ANDREW J | Director | A-Award | A | Common Stock | 4,100 | 0.00 | — | 11,125 | — | ↗ |
| 2022-06-14 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 16,800 | 0.00 | — | 16,800 | — | ↗ |
| 2022-06-14 | Lambert Nicole | Director | A-Award | A | Stock Option (Right to Buy) | 16,800 | 0.00 | — | 16,800 | — | ↗ |
| 2022-06-14 | Lacey David L. | Director | A-Award | A | Common Stock | 4,100 | 0.00 | — | 42,452 | — | ↗ |
| 2022-06-14 | KANEKO YASUNORI | Director | A-Award | A | Common Stock | 4,100 | 0.00 | — | 4,100 | — | ↗ |
| 2022-06-14 | FALBERG KATHRYN E | Director | A-Award | A | Stock Option (Right to Buy) | 16,800 | 0.00 | — | 16,800 | — | ↗ |
| 2022-03-16 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 9,617 | 31.62 | 304.1K | 105,978 | — | ↗ |
| 2022-03-08 | Tang Carolyn C. | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 33.03 | 2.15M | 65,000 | — | ↗ |
| 2022-03-08 | Jarrett Jennifer | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-03-08 | Jaen Juan C. | Officer | A-Award | A | Common Stock | 31,250 | 0.00 | — | 232,407 | — | ↗ |
| 2022-03-08 | Goeltz II Robert C. | Officer | A-Award | A | Stock Option (right to buy) | 62,500 | 33.03 | 2.06M | 62,500 | — | ↗ |
| 2022-03-07 | ROSEN TERRY J | Officer | A-Award | A | Common Stock | 65,000 | 0.00 | — | 276,570 | — | ↗ |
| 2022-02-28 | Jaen Juan C. | Director / Officer | G-Gift | D | Common Stock | 350,000 | 0.00 | — | 1,222,240 | — | ↗ |
| 2021-12-20 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 20,923 | 41.70 | 872.5K | 93,395 | — | ↗ |
| 2021-12-17 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 171 | 40.57 | 6.9K | 17,789 | — | ↗ |
| 2021-12-17 | ROSEN TERRY J | Director / Officer | S-Sale | D | Common Stock | 653 | 38.79 | 25.3K | 213,860 | — | ↗ |
| 2021-12-17 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 2,575 | 41.42 | 106.7K | 125,417 | — | ↗ |
| 2021-12-17 | Jaen Juan C. | Director / Officer | S-Sale | D | Common Stock | 157 | 39.67 | 6.2K | 201,862 | — | ↗ |
| 2021-12-17 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 224 | 41.42 | 9.3K | 7,019 | — | ↗ |
| 2021-12-16 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 131 | 40.46 | 5.3K | 18,186 | — | ↗ |
| 2021-12-16 | ROSEN TERRY J | Director / Officer | S-Sale | D | Common Stock | 619 | 40.46 | 25.0K | 214,513 | — | ↗ |
| 2021-12-16 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 1,496 | 40.46 | 60.5K | 132,535 | — | ↗ |
| 2021-12-16 | Jaen Juan C. | Director / Officer | S-Sale | D | Common Stock | 233 | 40.46 | 9.4K | 202,265 | — | ↗ |
| 2021-12-16 | Goeltz II Robert C. | Officer | S-Sale | D | Common Stock | 131 | 40.46 | 5.3K | 7,640 | — | ↗ |
| 2021-09-21 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 4,885 | 35.98 | 175.8K | 112,843 | — | ↗ |
| 2021-09-20 | Jarrett Jennifer | Director / Officer | S-Sale | D | Common Stock | 21,900 | 35.06 | 767.8K | 130,309 | — | ↗ |
| 2021-08-10 | Higgins Linda Slanec | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-03 | Lambert Nicole | Director | A-Award | A | Stock Option (Right to Buy) | 21,700 | 30.02 | 651.4K | 21,700 | — | ↗ |
| 2021-06-17 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 1,606 | 23.68 | 38.0K | 15,362 | — | ↗ |
| 2021-06-17 | ROSEN TERRY J | Director / Officer | S-Sale | D | Common Stock | 4,863 | 23.68 | 115.2K | 205,562 | — | ↗ |
| 2021-06-17 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 4,863 | 23.68 | 115.2K | 135,343 | — | ↗ |
| 2021-06-17 | Jaen Juan C. | Director / Officer | S-Sale | D | Common Stock | 2,675 | 23.68 | 63.3K | 198,286 | — | ↗ |
| 2021-06-17 | Grossman William | Officer | S-Sale | D | Common Stock | 3,891 | 23.68 | 92.1K | 20,723 | — | ↗ |
| 2021-06-16 | Tang Carolyn C. | Officer | S-Sale | D | Common Stock | 52 | 24.77 | 1.3K | 16,968 | — | ↗ |
| 2021-06-16 | ROSEN TERRY J | Director / Officer | S-Sale | D | Common Stock | 159 | 24.77 | 3.9K | 210,425 | — | ↗ |
| 2021-06-16 | Jarrett Jennifer | Officer | S-Sale | D | Common Stock | 159 | 24.77 | 3.9K | 140,206 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-574.0K
Shares Outstanding
100.67M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 775.0K | — | 2.20M | 6.01M | 658.8K | 14.8K | 9.66M | 85.00% | ↗ |
| 2 | 2025 | Richard Markus, M.D., Ph.D. Chief Medical Officer | 552.3K | 100.0K | 936.2K | 2.64M | 270.0K | 11.6K | 4.51M | 79.28% | ↗ |
| 3 | 2025 | Juan Carlos Jaen, Ph.D. President | 660.0K | — | 666.5K | 1.85M | 330.0K | 15.5K | 3.52M | 71.44% | ↗ |
| 4 | 2025 | Jennifer Jarrett Chief Operating Officer | 660.0K | — | 666.5K | 1.85M | 330.0K | 10.8K | 3.52M | 71.54% | ↗ |
| 5 | 2025 | Robert C. Goeltz, II Chief Financial Officer | 540.0K | — | 493.2K | 1.39M | 243.0K | 9.7K | 2.67M | 70.34% | ↗ |
| 6 | 2024 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 725.0K | — | 1.54M | 4.38M | 615.0K | 14.5K | 7.28M | 81.39% | ↗ |
| 7 | 2024 | Juan Carlos Jaen, Ph.D. President | 625.0K | — | 617.6K | 1.75M | 315.0K | 14.5K | 3.32M | 71.29% | ↗ |
| 8 | 2024 | Jennifer Jarrett Chief Operating Officer | 625.0K | — | 617.6K | 1.75M | 315.0K | 8.7K | 3.32M | 71.42% | ↗ |
| 9 | 2024 | Dimitry Nuyten, M.D., Ph.D. Chief Medical Officer | 585.0K | — | 432.3K | 1.23M | — | 261.8K | 2.51M | 66.21% | ↗ |
| 10 | 2024 | Robert C. Goeltz, II Chief Financial Officer | 510.0K | — | 339.7K | 934.7K | 230.0K | 8.7K | 2.02M | 62.99% | ↗ |
| 11 | 2023 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 650.0K | — | 2.33M | 6.58M | 550.0K | 11.1K | 10.12M | 88.03% | ↗ |
| 12 | 2023 | Juan Carlos Jaen, Ph.D. President | 575.0K | — | 1.01M | 2.85M | 300.0K | 14.5K | 4.75M | 81.27% | ↗ |
| 13 | 2023 | Jennifer Jarrett Chief Operating Officer | 575.0K | — | 1.01M | 2.85M | 300.0K | 8.7K | 4.74M | 81.37% | ↗ |
| 14 | 2023 | Dimitry Nuyten, M.D., Ph.D. Chief Medical Officer | 562.0K | — | 748.7K | 2.12M | 250.0K | 11.8K | 3.69M | 77.69% | ↗ |
| 15 | 2023 | Robert C. Goeltz, II Chief Financial Officer | 490.0K | — | 748.7K | 2.12M | 220.0K | 8.7K | 3.59M | 79.97% | ↗ |
| 16 | 2022 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 350.0K | — | 2.15M | 6.15M | 400.0K | 6.1K | 9.05M | 91.64% | ↗ |
| 17 | 2022 | Juan Carlos Jaen, Ph.D. President and Director | 550.0K | — | 1.03M | 2.79M | 370.0K | 11.1K | 4.76M | 80.42% | ↗ |
| 18 | 2022 | Juan Carlos Jaen, Ph.D. President | 550.0K | — | 1.03M | 2.79M | 370.0K | 11.1K | 4.76M | 80.42% | ↗ |
| 19 | 2022 | Jennifer Jarrett Chief Operating Officer | 550.0K | — | 1.03M | 2.79M | 370.0K | 5.3K | 4.75M | 80.52% | ↗ |
| 20 | 2022 | Jennifer Jarrett Chief Operating Officer and Director | 550.0K | — | 1.03M | 2.79M | 370.0K | 5.3K | 4.75M | 80.52% | ↗ |
| 21 | 2022 | Dimitry Nuyten, M.D., Ph.D. Chief Medical Officer | 225.0K | — | 1.11M | 3.11M | 160.0K | 337.00 | 4.61M | 91.63% | ↗ |
| 22 | 2022 | Robert C. Goeltz, II Chief Financial Officer | 470.0K | — | 512.0K | 1.40M | 270.0K | 5.3K | 2.65M | 71.92% | ↗ |
| 23 | 2021 | Jennifer Jarrett Chief Operating Officer and Director | 525.0K | — | 14.69M | — | 300.0K | 3.2K | 15.52M | 94.66% | ↗ |
| 24 | 2021 | Jennifer Jarrett Chief Operating Officer | 525.0K | — | 14.69M | — | 300.0K | 3.2K | 15.52M | 94.66% | ↗ |
| 25 | 2021 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 366.9K | 300.0K | 1.65M | 6.90M | — | 267.6K | 9.48M | 90.15% | ↗ |
| 26 | 2021 | Juan Carlos Jaen, Ph.D. President and Director | 535.0K | — | 711.6K | 2.86M | 300.0K | 5.6K | 4.42M | 80.96% | ↗ |
| 27 | 2021 | Juan Carlos Jaen, Ph.D. President | 535.0K | — | 711.6K | 2.86M | 300.0K | 5.6K | 4.42M | 80.96% | ↗ |
| 28 | 2021 | William Grossman, M.D., Ph.D. Former Chief Medical Officer | 317.3K | — | 688.7K | 2.92M | — | 2.9K | 3.93M | 91.85% | ↗ |
| 29 | 2021 | Robert C. Goeltz, II Chief Financial Officer | 435.0K | — | 459.1K | 1.85M | 175.0K | 2.8K | 2.92M | 79.01% | ↗ |
| 30 | 2021 | Carolyn Tang General Counsel | 400.0K | — | 460.5K | 1.85M | 200.0K | 3.2K | 2.92M | 79.32% | ↗ |
| 31 | 2020 | Jennifer Jarrett Chief Operating Officer and Director | 125.0K | — | 90.2K | 10.58M | 75.0K | 28.2K | 10.90M | 97.91% | ↗ |
| 32 | 2020 | William Grossman, M.D., Ph.D. Chief Medical Officer | 457.6K | — | 3.35M | 2.07M | 250.0K | 1.2K | 6.13M | 88.45% | ↗ |
| 33 | 2020 | William Grossman, M.D., Ph.D. Former Chief Medical Officer | 457.6K | — | 3.35M | 2.07M | 250.0K | 1.2K | 6.13M | 88.45% | ↗ |
| 34 | 2020 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 325.6K | — | 3.01M | 2.35M | — | 3.6K | 5.69M | 94.21% | ↗ |
| 35 | 2020 | Juan Carlos Jaen, Ph.D. President and Director | 515.0K | — | 1.65M | 1.34M | 275.0K | 3.6K | 3.79M | 79.06% | ↗ |
| 36 | 2020 | Robert C. Goeltz, II Chief Financial Officer | 175.0K | — | — | 3.51M | 75.0K | 338.00 | 3.76M | 93.34% | ↗ |
| 37 | 2020 | Carolyn Tang General Counsel | 337.5K | — | 958.7K | 767.1K | 175.0K | 1.2K | 2.24M | 77.06% | ↗ |
| 38 | 2019 | Rekha Hemrajani Former Chief Operating Officer and Chief Financial Officer | 233.8K | 200.0K | — | 2.98M | — | 142.3K | 3.56M | 83.81% | ↗ |
| 39 | 2019 | William Grossman, M.D., Ph.D. Former Chief Medical Officer | 296.7K | 200.0K | — | 2.72M | 180.0K | 600.00 | 3.40M | 80.08% | ↗ |
| 40 | 2019 | William Grossman, M.D., Ph.D. Chief Medical Officer | 296.7K | 200.0K | — | 2.72M | 180.0K | 600.00 | 3.40M | 80.08% | ↗ |
| 41 | 2019 | Juan Carlos Jaen, Ph.D. President and Director | 500.0K | — | — | 1.38M | 250.0K | 1.2K | 2.13M | 64.68% | ↗ |
| 42 | 2019 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 340.0K | — | — | 1.38M | — | 1.2K | 1.72M | 80.13% | ↗ |
| 43 | 2018 | Jennifer Jarrett Former Chief Operating Officer and Chief Financial Officer | 435.9K | — | — | 2.67M | 200.0K | 1.2K | 3.30M | 80.71% | ↗ |
| 44 | 2018 | Juan Carlos Jaen President and Director | 350.0K | — | — | 828.3K | — | 1.2K | 1.18M | 70.22% | ↗ |
| 45 | 2018 | Juan Carlos Jaen, Ph.D. President and Director | 350.0K | — | — | 828.3K | — | 1.2K | 1.18M | 70.22% | ↗ |
| 46 | 2018 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 295.0K | — | — | 828.3K | — | 1.2K | 1.12M | 73.66% | ↗ |
| 47 | 2017 | Jennifer Jarrett Former Chief Operating Officer and Chief Financial Officer | 333.3K | — | — | 460.8K | 100.0K | 900.00 | 895.1K | 51.49% | ↗ |
| 48 | 2017 | Juan Carlos Jaen President and Director | 350.0K | — | — | 110.8K | — | 1.2K | 462.0K | 23.98% | ↗ |
| 49 | 2017 | Terry Rosen, Ph.D. Chief Executive Officer and Director | 314.8K | — | — | 110.8K | — | 1.2K | 426.8K | 25.96% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Terry J. Rosen | Co-Founder, Chairman & Chief Executive Officer | 1M | — |
| Juan Carlos Jaen | Co- Founder & President | 1M | — |
| Jennifer A. Jarrett | Advisor | 1M | female |
| Richard A. Markus | Chief Medical Officer | 933.9K | — |
| Robert C. Goeltz | Principal Financial Officer & Chief Financial Officer | 792.7K | male |
| Carolyn C. Tang | General Counsel & Corporate Secretary | 603.2K | female |
| Yvonne Gehring | Senior Vice President of Human Resources | — | female |
| Holli Kolkey | Vice President of Corporate Communications | — | — |
| Jonathan Yingling | Chief Scientific Officer | — | — |
| K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board | — | — |
| Pia Eaves | Vice President of Investor Relations & Strategy | — | — |
| Alexander Azoy | Chief Accounting Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RCUS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
